Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Paroxysmal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    204 result(s) found for: Paroxysmal. Displaying page 3 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-004403-14 Sponsor Protocol Number: BCX9930-203 Start Date*: 2021-11-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Noct...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) LT (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000665-79 Sponsor Protocol Number: ACH471-103 Start Date*: 2018-07-23
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment with ACH-0144471 in Patients with PNH who Completed Clinical Study ACH471-100
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000094-76 Sponsor Protocol Number: FLE-002 Start Date*: 2018-05-02
    Sponsor Name:InCarda Therapeutics, Inc.
    Full Title: A prospective, randomized, multicenter study of flecainide acetate oral inhalation solution in single and repeat dose regimens for acute conversion to sinus rhythm (SR) in subjects with recent onse...
    Medical condition: Acute conversion to sinus rhythm (SR) in subjects with recent onset of symptomatic paroxysmal atrial fibrillation (AF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005338-74 Sponsor Protocol Number: CLFG316X2201 Start Date*: 2015-06-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Medical condition: Paroxysmal nocturnal hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002128-10 Sponsor Protocol Number: BP39144 Start Date*: 2016-09-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed) DE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004931-21 Sponsor Protocol Number: BO42162 Start Date*: 2020-10-26
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTUR...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) PL (Trial now transitioned) GR (Completed) PT (Trial now transitioned) BE (Completed) IE (Prematurely Ended) NL (Trial now transitioned) EE (Completed) LT (Trial now transitioned) IT (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005140-16 Sponsor Protocol Number: APL2-202 Start Date*: 2018-07-18
    Sponsor Name:Apellis Pharmaceuticals
    Full Title: A Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001134-42 Sponsor Protocol Number: GS-US-291-0102 Start Date*: 2012-05-22
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation bur...
    Medical condition: Paroxysmal Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003172-41 Sponsor Protocol Number: CLNP023C12301 Start Date*: 2021-06-03
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naive to complement inhibitor therapy
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001106-23 Sponsor Protocol Number: APL2-307 Start Date*: 2019-08-09
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000597-26 Sponsor Protocol Number: BO42161 Start Date*: Information not available in EudraCT
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PA...
    Medical condition: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004317-40 Sponsor Protocol Number: ADRAMIO001 Start Date*: 2014-06-23
    Sponsor Name:The Heart Centre, Rigshospitalet
    Full Title: Adrenaline versus amiodarone for out of hospital cardiac arrest due to shockable rhythms (ventricular fibrillation and pulseless ventricular tachycardia) - ADRAMIO. A randomized, double blind, mu...
    Medical condition: Out of hospital cardiac arrest due to ventricular fibrillation.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10047293 Ventricular fibrillation paroxysmal LLT
    17.0 100000004849 10066685 Recurrent ventricular fibrillation LLT
    17.0 100000004849 10034048 Paroxysmal ventricular fibrillation LLT
    17.0 100000004849 10047292 Ventricular fibrillation paroxysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003830-17 Sponsor Protocol Number: ACH228-110 Start Date*: 2020-09-16
    Sponsor Name:Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
    Full Title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004486-40 Sponsor Protocol Number: R3918-PNH-2021 Start Date*: 2022-04-04
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004268-36 Sponsor Protocol Number: APL2-302 Start Date*: 2018-10-01
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic epis...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002761-33 Sponsor Protocol Number: R3918-PNH-2022 Start Date*: 2022-05-02
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: A RANDOMIZED, OPEN-LABEL ECULIZUMAB AND RAVULIZUMAB CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGL...
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) PL (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000308-41 Sponsor Protocol Number: MSP-2017-1138 Start Date*: 2020-12-14
    Sponsor Name:Milestone Pharmaceuticals Inc.
    Full Title: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardi...
    Medical condition: Treatment of Paroxysmal Supraventricular Tachycardia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10034044 Paroxysmal supraventricular tachycardia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) PL (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002442-45 Sponsor Protocol Number: AXAFA-AFNET5 Start Date*: Information not available in EudraCT
    Sponsor Name:Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)]
    Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.
    Medical condition: Atrial fibrillation catheter ablation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    19.0 10007541 - Cardiac disorders 10071667 Persistent atrial fibrillation LLT
    19.0 10007541 - Cardiac disorders 10003661 Atrial fibrillation paroxysmal LLT
    19.0 10007541 - Cardiac disorders 10066582 Recurrent atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002809-23 Sponsor Protocol Number: CV131-235 Start Date*: 2005-11-18
    Sponsor Name:Bristol-Myers Squibb SL
    Full Title: Electrophysiological effects of Irbesartan in patients with paroxysmal AF Efectos electrofisiológicos del Irbesartán en sujetos con FA paroxística
    Medical condition: Patients with paroxysmal atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002208-14 Sponsor Protocol Number: Protocol v.1.2 30/08/04 Start Date*: 2005-02-21
    Sponsor Name:Cardiff and Vale NHS Trust
    Full Title: Duration of Amiodarone therapy required for new post cardiac surgery atrial fibrillation.
    Medical condition: Atrial fibrillation following cardiac surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:26:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA